BONESUPPORT AB articles

BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During August, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 10,000 due to the exercise of warrants.  

As of 31 August 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,440,318 shares, of which 64,150,318 are ordinary shares with one vote per share and

BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced inconclusive results for the company’s Investigational Device Exemption (IDE) study; FORTIFY. The primary safety endpoint for CERAMENT G was met.

The FORTIFY study was initiated in 2017 with the purpose to evaluate the ability of CERAMENT G to improve the treatment outcomes for patients with open tibia fractures G-A II-I